J Rheum Dis.  2015 Aug;22(4):263-268. 10.4078/jrd.2015.22.4.263.

Appearance of Psoriasis after Tumor Necrosis Factor-alpha Blocker and Use of Ustekinumab or Tocilizumab for Refractory Monoarthritis

• Moon J
• Kwak N
• Lim J
• Go DJ
• Lee JH
• Park JK
• Lee EB
• Song YW
• Youn JI
• Lee EY

• KMID: 2222860
• DOI: http://doi.org/10.4078/jrd.2015.22.4.263

Abstract

Nowadays, tumor necrosis factor-alpha (TNF-alpha) blockers are used for treatment of rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis, psoriatic arthritis, and psoriasis. Paradoxically, there are some reports on the appearance of psoriasis after administration of TNF-alpha blockers. Here, we report on a patient with monoarthritis in a knee joint who experienced psoriasis after TNF-alpha blocker therapy (adalimumab and etanercept). Oral medication was not a treatment option due to patient intolerance; thus, we tried ustekinumab, an anti-interleukin (IL)-12/23 monoclonal antibody used for treatment of psoriasis. Following ustekinumab injection, psoriatic skin lesions and joint symptoms were much improved. However, in the following period, joint pain and swelling became aggravated and synovial fluid cytokine levels including IL-6 and IL-17 were elevated. The treatment was changed to tocilizumab, a humanized monoclonal antibody against IL-6 receptor. After injection, knee joint swelling rapidly subsided without worsening of psoriatic skin lesions.

Keyword

Tumor necrosis factor-alpha blocker; Monoarthritis; Psoriasis; Ustekinumab; Tocilizumab

MeSH Terms

Arthralgia
Arthritis, Psoriatic
Arthritis, Rheumatoid
Humans
Inflammatory Bowel Diseases
Interleukin-17
Interleukin-6
Joints
Knee Joint
Psoriasis*
Receptors, Interleukin-6
Skin
Spondylitis, Ankylosing
Synovial Fluid
Tumor Necrosis Factor-alpha*
Ustekinumab
Interleukin-17
Interleukin-6
Receptors, Interleukin-6
Tumor Necrosis Factor-alpha